Posted by Michael Wonder on 16 Oct 2023
Health economic assessment of Enhertu in breast cancer
13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions.
The assessment concerns the treatment of certain adult patients with breast cancer who express low levels of HER2.
